Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2009

Conditions

Healthy

Interventions

DRUG

BI 207127 NA (TF-I)

200 mg tablet

DRUG

BI 207127 NA (TF-II)

400 mg tablet

DRUG

BI 207127 NA delayed release

400 mg tablet

DRUG

BI 207127 NA extended release (10% HPMC)

400 mg tablet

DRUG

BI 207127 NA extended release (15% PEO)

400 mg tablet

DRUG

BI 207127 NA extended release (20% HPMC)

400 mg tablet